# OnCo record profile-1001-ros1 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/profile-1001-ros1/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "profile-1001-ros1", "NCT00585195" ;
  schema:name "PROFILE 1001 ROS1 expansion cohort"@en ;
  schema:alternateName "Crizotinib in ROS1-rearranged NSCLC"@en ;
  schema:description "Fifty patients in an expansion cohort defined ROS1 as the second treatable fusion in lung cancer and put crizotinib on the label for it."@en ;
  schema:url <https://onco.cc/trials/profile-1001-ros1/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT00585195>, <https://doi.org/10.1056/NEJMoa1406766>, <https://www.nice.org.uk/guidance/ta1021> ;
  onco:status "positive" ;
  onco:phase "1" ;
  onco:cancers <https://onco.cc/cancers/ros1-positive-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/ros1/> ;
  onco:drugs <https://onco.cc/drugs/crizotinib/>, <https://onco.cc/drugs/entrectinib/>, <https://onco.cc/drugs/repotrectinib/> ;
  onco:companies <https://onco.cc/companies/pfizer/> ;
  onco:terms <https://onco.cc/terms/gene-fusion/>, <https://onco.cc/terms/oncogene-addiction/>, <https://onco.cc/terms/tki-term/> ;
  onco:trials <https://onco.cc/trials/nct03093116/>, <https://onco.cc/trials/nct02568267/> .